Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 90Other hematologic neoplasm 58Breast 42CNS 31Sarcoma 24Plasma cell 20Genitourinary 8Myeloid 6Gynecologic 4Classical hematology 4Dermatologic 3Other neoplasm 2Thoracic 1Other solid neoplasm 1Endocrine 1

Conditions

Wilms Tumor 1Sarcoma 1Retinoblastoma 1Neuroblastoma 1Kidney Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Filgrastim 3Doxorubicin 3Temozolomide 2Octreotide 2Ifosfamide 2Etoposide 2Cisplatin 2Capecitabine 2vatalanib 1vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1telotristat ethyl 1pegfilgrastim 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lanreotide 1batifiban 1Suramin 1Radiotherapy 1Platinum 1Mitotane 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Everolimus 1Ethane 1Docetaxel 1Dichlorodiphenyldichloroethane 1DNA Methylation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Cyclophosphamide × Endocrine × Clear all
NCT01048892 2014-01-30

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Children's Oncology Group

Phase 1 Completed
22 enrolled
CNSEndocrineGenitourinaryOther solid neoplasmSarcoma

Kidney Neoplasms, Wilms Tumor, Neuroblastoma, Retinoblastoma, Sarcoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡